Kodiak Sciences - Novel medicines for retinal disease

Kodiak Sciences is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases

OUR MISSION

Kodiak aims to prevent and treat the leading causes of blindness in the developed world

TRAILBLAZING SCIENCE

OUR CREATIVE AND THOUGHTFUL FOUNDATION

“GO-TO” MEDICINES

OUR CHALLENGE TO THE STATUS QUO

SINGULAR FOCUS IN OPHTHALMOLOGY

OUR 24/7/365

OUR PRODUCT CANDIDATES

We intend to progress our portfolio of late-phase clinical assets across a broad spectrum of retinal diseases as rapidly as we can into Phase 3 value inflection points

Tarcocimab Tedromer

High-prevalence retinal
vascular diseases

Wet AMD
Diabetic retinopathy
Retinal vein occlusion

Phase 3

KSI-501

High-prevalence retinal
vascular diseases

Indications of interest include wet AMD, diabetic macular edema, retinal vein occlusion and diabetic retinopathy

Phase 3

KSI-101

Macular edema
secondary to inflammation

Phase 1b

Explore our pipeline →

Slide

Tarcocimab tedromer

Anti-VEGF ABCD

Tarcocimab is our most advanced program. We have important learnings from six pivotal studies across four major retinal diseases and maintain our conviction that tarcocimab could be an important medicine. With tarcocimab’s signature durability and safety record, as demonstrated in multiple studies, we believe tarcocimab could be differentiated in the market as a longest-acting biologic based on its Antibody Biopolymer Conjugate Drug (ABCD) Platform design.

Our objective is to finish the clinical development program and enable the marketing application. We intend to do this using the enhanced formulation of conjugated and unconjugated forms that we believe balances towards durability without compromising immediacy. Learn more

Tarcocimab is our most advanced program. We have important learnings from six pivotal studies across four major retinal diseases and maintain our conviction that tarcocimab could be an important medicine. With tarcocimab’s signature durability and safety record, as demonstrated in multiple studies, we believe tarcocimab could be differentiated in the market as a longest-acting biologic based on its ABCD Platform design. Our objective is to finish the clinical development program and enable the marketing application. Learn more

Slide

KSI-501

Bispecific anti-IL-6, VEGF trap ABCD

KSI-501 is first-in-class bispecific Antibody Biopolymer Conjugate Drug (ABCD) designed to address the opportunity for improved efficacy with extended durability in high-prevalence retinal vascular diseases by targeting retinal inflammation and vascular permeability simultaneously.

The pathophysiology of retinal vascular and hyperpermeability disorders is multifactorial. In addition to VEGF-mediated fluid and leakage, IL-6 stimulates defective angiogenesis, is implicated in anti-VEGF treatment resistance, and is associated with disease progression in high-prevalence retinal diseases. Learn more

KSI-501 is a first-in-class, anti-IL-6, VEGF trap bispecific antibody biopolymer conjugate built on our Antibody Biopolymer Conjugate Drug (ABCD) platform and is being developed for high-prevalence retinal vascular diseases to address the unmet needs of targeting multiple biologies and extended durability. Learn more

Slide

KSI-101

Bispecific anti-IL-6, VEGF trap protein

KSI-101 is a potent 100 mg/mL high-strength bispecific protein being developed for the treatment of macular edema secondary to inflammation.

Currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina. We believe that KSI-101 has the potential to meaningfully help patients with retinal fluid and inflammation by being a first-in-class biologic that addresses the underlying disease mechanisms of IL-6-mediated inflammation and edema, and VEGF-mediated vascular permeability. Learn more

KSI-101 is a novel bispecific protein targeting IL-6 and VEGF for the treatment of macular edema associated with inflammation.

THE ABCD OF OUR SCIENCE

We are bringing new science to the design and development of next generation retinal medicines. Our Antibody Biopolymer Conjugate Drug (ABCD) Platform uses a bio-inspired polymer to enable multi-modal, multi-mechanistic treatment of complex ocular and systemic diseases

Antibody Biopolymer Conjugate Drug

Biopolymer

Biopolymer + Antibody

Conjugate

Conjugate + Labels

Designed-in durability
Designed to target multiple intracellular and extracellular mechanisms simultaneously
Designed for ocular and systemic diseases

Learn more about the science of our ABCD Platform →

OUR CULTURE AND VALUES

We are actively building a place, our Kodiak Village, where we are inspired, where we feel valued, and where we can grow our personal and professional journeys while advancing our mission. Historically referred to within Kodiak as the 4 C’s, our values are: